 |
SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant...
Businesses across Sydney are now quickly coming out of lockdown. With 2022 just around the corner, it’s important that businesses adapt to the new...
Buying or selling a property in a particular area of the world can often require you to work with a real estate company. In addition, if you want ...
More and more Australians are choosing to build granny flats, and for a good reason! They provide additional living space for elderly parents or a...
Wearing a mask wears you out. Faking it is fatiguing. The most exhausting activity is pretending to be what you know you aren’t. – Rick Warren ...
We all know how colorless life can be without the audio in it. And with the broad range of digital media that surrounds us wherever we go, we all ne...
Pursuing a Master of Business Administration (MBA) degree is a significant decision that requires careful planning and preparation. As the competi...